The George InstituteVerified account


The George Institute for changes lives by delivering innovative that influences and practice worldwide.

Joined May 2009


You blocked @georgeinstitute

Are you sure you want to view these Tweets? Viewing Tweets won't unblock @georgeinstitute

  1. Pinned Tweet

    New breakthrough treatment for offers hope for hundreds of millions of people with worldwide:

    , , and 7 others
  2. Our Senior Advocacy Advisor, Emma Feeny adds vital context looking beyond 's stats report which disaggregates data by sex for the first time:

  3. Apr 18

    Are you interested in finding out how to develop & deliver a national policy? This yer's sell-out symposium will offer global perspectives. Waitlist operating at & follow our Distinguished Fellow for updates

  4. Apr 18

    in most cities is ↑, as is associated burden. food provisioning – the way people in cities access food – is significant part of the problem. So, how to respond? Join us 20th June to discuss

  5. Join Dr at on 1st May for a special talk on a program of work to end rheumatic heart disease. Free Registration:

  6. A new treatment for people with diabetes and kidney disease reduced kidney failure rates by a third:

  7. Apr 17

    The Food Policy Team at The George is looking for a Research Fellow with super skills in stats to come play with Nielsen sales data - come join us!

  8. Apr 18
  9. Apr 18

    Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy | NEJM great news for people with diabetes - congratulations to the team and partners

  10. Apr 17

    Hear a summary of the CREDENCE study

  11. Harnessing the power of digital technologies is essential for achieving universal health coverage. has released our first guideline on interventions, which are vital tools to promote health, keep the world safe, & serve the vulnerable.

  12. Apr 17

    Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy |

  13. Apr 17

    Fantastic news from "In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years."

  14. Undo
  15. Apr 17

    The fact that decided to release a statement on is a clear indication of how significant this trial is

  16. Apr 17

    BLOG Our Senior Advocacy Advisor, Emma Feeny, looks beyond headline stats report which disaggregates data by sex for the first time, to add vital context:

  17. Apr 17

    Dr serves as an invited expert on the Guidelines Development Group. Here is what he has to say about the 10 recommendations in 's guideline recommendations on launched today:

    , , and 6 others
    Show this thread
  18. Download 's first guideline recommendations on Interventions for Health System Strengthening:

  19. Apr 17

    "not only protects people w/ from developing , but also protects them from , & other complications” Dr Meg Jardine & from What are your thoughts on ?

  20. Apr 16

    BREAKING NEWS for patients with diabetic ! Data published in shows that INVOKANA (Canagliflozin) can help patients diagnosed with type 2 and reduce the risk of end stage renal disease and cardiovascular events.

  21. Apr 16

    Download the late-breaking pptx formatted slides here where you will find some keepers. I grateful to the people with T2DM and CKD that participated in the trial. I commend the investigators from design to tour de force presentation in Melbourne, Australia.


Loading seems to be taking a while.

Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.

    You may also like